Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Henry Niman who wrote (6023)	2/1/1999 10:28:00 AM
From: Oliver & Co	of 6136

"Abbott Laboratories to Present Findings of Viral-Reducing AIDS Drug Today" Wall Street Journal (www.wsj.com) (02/01/99) P. B8; Burton, Thomas M. Abbott Laboratories plans Monday to release clinical findings that show its experimental AIDS drug, ABT-378, reduced viral loads to below-detectable levels in 90 percent of patients when the drug was combined with an existing AIDS drug, Abbott's Norvir. Because the study, which is to be reported in Chicago at the Sixth Conference on Retroviruses and Opportunistic Infections, only involved patients who had never received treatment with other protease-inhibitors, researchers said they were unsure how the treatment would affect patients who previously used other protease drugs. The researchers also noted the drug caused minimal short-term side effects, such as headache and diarrhea, and that no patients stopped participating in the trial because of side effects, which they emphasized is very unusual. Abbott said the drug was about half way through clinical trials and that it expected to submit a marketing application to the Food and Drug Administration in mid-2000.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next